A CALCIUM-RICH MULTI-MINERAL INTERVENTION TO MODULATE COLONIC MICROBIAL COMMUNITIES AND METABOLOMIC PROFILES IN HUMANS: Results from a 90-day trial - Aslam, Muhammad N.; Bassis, Christine M.; Bergin, Ingrid L.; Knuver, Karsten; Zick, Suzanna M.; Sen, Ananda; Turgeon, D. Kim; Varani, James (medRxiv, 2019)
Aquamin, a calcium-, magnesium-, and multiple trace element-rich natural product has polyp prevention efficacy based on preclinical studies. The overall goal of this study was to determine the safety and tolerability of Aquamin when used as a dietary chemopreventative in humans. Additionally, we determined the effects of Aquamin on the colonic microbial community and attendant metabolomic profile. Thirty healthy male and female human participants were enrolled in a 90-day trial in which the effects of Aquamin (delivering 800 mg of calcium per day) were compared to those of calcium alone or placebo. Before and after the interventional period, colonic biopsies and stool specimens were obtained. All 30 participants completed the study without serious adverse events. There were no changes in liver function markers. Compared to pretreatment values, intervention with Aquamin led to a reduction in total bacterial DNA and a shift in the microbial community. Treatment with calcium alone also produced a decline in total bacteria, but smaller than seen with Aquamin, while no reduction was observed with placebo. In parallel with microbial changes, a reduction in bile acid levels and a slight increase in the level of the short chain fatty acid (SCFA) acetate in stool specimens from Aquamin-treated participants was noted. No change in bile acids or SCFAs was observed with calcium alone or placebo. We conclude from these studies that Aquamin is safe and tolerable in healthy human participants and may produce beneficial alterations in the colonic microbial community and the attendant metabolomic profile.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02647671Funding StatementThis study was supported by NIH grants CA201782 to JV, UL1TR002240 to the Michigan Institute for Clinical & Health Research and 2 P30 DK089503-06 to the Michigan Nutrition and Obesity Research Center (MNORC). Metabolomic work was supported by Pilot/Feasibility Grant from MNORC to IB and MNA. This study also used services at the University of Michigan which were supported by NIH funding (UL1TR002240; KL2TR002241; and TL1TR002242) to the Michigan Institute for Clinical & Health Research (MICHR).Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.YesI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesMicrobial sequencing data will be available from the NCBI Sequence Read Archive database, accession number is pending. Raw bile acid (metabolomic) data will be available in UCSD Metabolomics Workbench, a metabolomic repository, study ID is pending.aMCAalpha-MurocholatebMCAbeta-MuricholateCACholateCDCAChenodeoxycholateDCADeoxycholateGCAGlycocholateGCDCAGlycochenodeoxycholateGDCAGlycodeoxycholateGHCAGlycohyocholateGHDCAGlycohyodeoxycholateGUDCAGlycoursodeoxycholateHCAHyocholateHDCAHyodeoxycholateLCALithocholateTaMCATauro-alpha-muricholateTbMCATauro-beta-muricholateTCATaurocholateTCDCATaurochenodeoxycholateTDCATaurodeoxycholateTHCATaurohyocholateTHDCATaurohyodeoxycholateTLCATaurolithocholateTUDCATauroursodeoxycholateUDCAUrsodeoxycholatewMCAomega-Muricholate